TQB3454
Phase 3Small molecule
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.TQB3454 is one of 13 small molecule programs targeting Carcinoma. It is currently in Phase 3.
1
Indications
4
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
22 competitors in Carcinoma
#DrugCompanyPhaseTrials
1Afinitor
NovartisPhase 3
Fludara
SanofiPhase 2
Cytoxan
BBaxter Healthcare Corporation
Phase 2
Klisyri
AAlmirall, S.A.
Phase 2
TQB3454
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Administration of AVP
AAssistance Publique - Hôpitaux de Paris
Preclinical
SZ011 CAR-NK
SShantou University Medical College
Phase 1
Ga-NOTA-T4
RRenJi Hospital
Preclinical
F-RESCA-T4
RRenJi Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Carcinoma1 trial
A Clinical Study of TQB3454 Tablets in the Treatment of Advanced Biliary Carcinoma.
Active, not recruiting·Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT05987358·165 enrolled
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT05987358·165 enrolledSources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for TQB3454. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details